Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cagrilintide D · 1 trial · 2 indications
Measured in hour nanomoles per litre (h\*nmol/L)
Measured in nanomoles per litre (nmol/L).
| Arm | Type | Description |
|---|---|---|
| Cagrilintide B and Placebo Semaglutide I | EXPERIMENTAL | Participants will receive Cagrilintide B and Placebo semaglutide I subcutaneously once weekly for up to 17 weeks. |
| Cagrilintide D-Injection site 1 | EXPERIMENTAL | Participants will receive Cagrilintide D subcutaneously once weekly for up to 17 weeks. |
| Cagrilintide D-Injection site 2 | EXPERIMENTAL | Participants will receive Cagrilintide D subcutaneously once weekly for up to 17 weeks. |
| Cagrilintide D-Injection site 3 | EXPERIMENTAL | Participants will receive Cagrilintide D subcutaneously once weekly for up to 17 weeks. |
| Name | Type | Description |
|---|---|---|
| Cagrilintide D | DRUG | Cagrilintide D will be administered subcutaneously. |
| Cagrilintide B and placebo semaglutide I | DRUG | Cagrilintide B and placebo semaglutide I will be administered subcutaneously |
Inclusion Criteria: * Aged 18-64 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) between 27.0 and 34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator. * Consi...
Top 20 of 32 competitors
Cagrilintide D is an investigational small molecule being developed for obesity. It is a peptide-based therapy under evaluation in adults with overweight or obesity. The drug is in Phase 1 clinical development and is not yet approved by regulatory authorities.
Cagrilintide D is being developed by Novo Nordisk A/S, a biopharmaceutical company traded on the stock exchange under the ticker NVO. The company is conducting clinical research to evaluate the drug's properties in adults with overweight or obesity.
Cagrilintide D is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies. The ongoing Phase 1 trial is recruiting participants to study blood levels of the drug after multiple doses.
Cagrilintide D is being studied in a Phase 1 clinical trial with the identifier NCT07597018. This recruiting study, conducted in Germany, compares blood levels of different versions of cagrilintide after multiple doses in adults with overweight or obesity. The trial has an enrollment target of 234 participants.
Cagrilintide D is a version of cagrilintide being studied by Novo Nordisk. The clinical trial NCT07597018 is designed to compare blood levels of different versions of cagrilintide, including Cagrilintide D, after multiple doses in adults with overweight or obesity.